The FertiGen® Story
In early 2015, a decision was taken to open the Center for Advanced Genetics (CAG), a small private reproductive endocrinology practice midway between Los Angeles & San Diego.
CAG entered the competitive California IVF arena, attaining pregnancy rates consistently above national average and grew quickly.
Soon this boutique clinic was registered as the first U.S. site to study ovarian treatment with platelet derived growth factors.
Although initially skeptical, Dr. Sills revised his view on platelet cytokines as data from the fresh plasma clinical trial showed that this approach deserved more attention.
The FertiGen marque was obtained first to set safe standards for this technology, and a provisional U.S. Patent followed next.
Today the expertise of Dr. Scott Sills drives the science behind this clinical research platform. His research with Regenerative Biology Group (HK) and PRP.md continues.
Hormonal profile changes measured after his FertiGen method can reveal boosted reproductive capacity, where ovaries once considered dormant are reawakened.